Literature DB >> 16025549

Continuous Bayesian adaptive randomization based on event times with covariates.

Ying Kuen Cheung1, Lurdes Y T Inoue, J Kyle Wathen, Peter F Thall.   

Abstract

In comparative clinical trials, the randomization probabilities may be unbalanced adaptively by utilizing the interim data available at each patient's entry time to favour the treatment or treatments having comparatively superior outcomes. This is ethically appealing because, on average, more patients are assigned to the more successful treatments. Consequently, physicians are more likely to enroll patients onto trials where the randomization is outcome-adaptive rather than balanced in the conventional manner. Outcome-adaptive methods based on a binary variable may be applied by reducing an event time to the indicator of the event's occurrence within a predetermined time interval. This results in a loss of information, however, since it ignores the censoring times of patients who have not experienced the event but whose evaluation interval is not complete. This paper proposes and compares exact and approximate Bayesian outcome-adaptive randomization procedures based on time-to-event outcomes. The procedures account for baseline prognostic covariates, and they may be applied continuously over the course of the trial. We illustrate these methods by application to a phase II selection trial in acute leukaemia. A simulation study in the context of this trial is presented. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16025549     DOI: 10.1002/sim.2247

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  20 in total

1.  Do commonly used clinical trial designs reflect clinical reality?

Authors:  Elihu Estey
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

Review 2.  Randomized phase II trials: a long-term investment with promising returns.

Authors:  Manish R Sharma; Walter M Stadler; Mark J Ratain
Journal:  J Natl Cancer Inst       Date:  2011-06-27       Impact factor: 13.506

3.  Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.

Authors:  Stuart A Grossman; Karisa C Schreck; Karla Ballman; Brian Alexander
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

4.  Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials.

Authors:  P Thall; P Fox; J Wathen
Journal:  Ann Oncol       Date:  2015-05-15       Impact factor: 32.976

5.  Continuous evaluation of evolving behavioral intervention technologies.

Authors:  David C Mohr; Ken Cheung; Stephen M Schueller; C Hendricks Brown; Naihua Duan
Journal:  Am J Prev Med       Date:  2013-10       Impact factor: 5.043

6.  Outcome--adaptive randomization: is it useful?

Authors:  Edward L Korn; Boris Freidlin
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

7.  Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial.

Authors:  Sean P Collins; Christopher J Lindsell; Peter S Pang; Alan B Storrow; W Frank Peacock; Phil Levy; M Hossein Rahbar; Deborah Del Junco; Mihai Gheorghiade; Donald A Berry
Journal:  Am Heart J       Date:  2012-07-09       Impact factor: 4.749

8.  A response-adaptive design of initial therapy for emergency department patients with heart failure.

Authors:  Sijin Wen; Jing Ning; Sean Collins; Donald Berry
Journal:  Contemp Clin Trials       Date:  2016-11-09       Impact factor: 2.226

9.  RARtool: A MATLAB Software Package for Designing Response-Adaptive Randomized Clinical Trials with Time-to-Event Outcomes.

Authors:  Yevgen Ryeznik; Oleksandr Sverdlov; Weng Kee Wong
Journal:  J Stat Softw       Date:  2015-08-01       Impact factor: 6.440

10.  Using short-term response information to facilitate adaptive randomization for survival clinical trials.

Authors:  Xuelin Huang; Jing Ning; Yisheng Li; Elihu Estey; Jean-Pierre Issa; Donald A Berry
Journal:  Stat Med       Date:  2009-05-30       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.